Lianyungang Runzhong

Lianyungang Runzhong Pharmaceutical Co., Ltd. is a prominent Chinese pharmaceutical manufacturer and a key subsidiary of Chia Tai Tianqing Pharmaceutical Group, which is part of the Sino Biopharmaceutical conglomerate. Established in 2010 and headquartered in Lianyungang, the company focuses on the production of active pharmaceutical ingredients (APIs) and finished drug products across several therapeutic areas, most notably anti-infectives and oncology. Its flagship product, Runzhong (Entecavir), is a leading treatment for chronic hepatitis B in the Chinese market. The company maintains advanced manufacturing facilities that comply with international GMP standards, supporting both domestic supply and global export initiatives for its parent group.